Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) reported the repurchase of 64,800 ordinary shares on 29 April 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices ranging from HK$7.05 to HK$7.10, for a total consideration of HK$0.46 million, implying a volume-weighted average price of HK$7.08 per share. All repurchased shares have been retained as treasury stock.

Following the transaction, Jacobio Pharma’s outstanding share capital (excluding treasury shares) fell by 0.008 % to 785.28 million shares. Treasury shares increased to 6.48 million, while total issued shares remained unchanged at 791.76 million.

The buyback was executed under the mandate approved on 10 June 2025, which authorises the company to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.46 million shares, representing 0.44 % of the company’s issued share count at the time the mandate was granted. No repurchased shares have been cancelled to date.

In accordance with Hong Kong listing rules, Jacobio Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 29 May 2026.